Drug intelligence / Profile preview

RJ011

Development stage: Preclinical
Lead developer: Risen
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

RJ011 is a small interfering RNA (siRNA) therapeutic candidate under development by Risen Shanghai Medical Technology (also known as Runjia Shanghai Pharmaceutical Technology) for the treatment of metabolic diseases. The drug utilizes RNA interference to silence the expression of a specific, currently undisclosed, genetic target involved in metabolic regulation. It is part of Risen's broader siRNA platform, which includes other metabolic programs such as RP912 and RP910. RJ011 is currently in the preclinical stage of discovery and development.

Beyond the preview

Go deeper on RJ011.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RJ011.

Explore the full profile